Immediate ART Following Diagnosis of an AIDS-Related OI: Is It Cost-Effective?

A mathematical model suggests that starting ART within 2 weeks after diagnosis of an AIDS-related opportunistic infection is cost-effective compared to delaying ART.

The ACTG A5164 trial showed significant benefits to starting antiretroviral therapy (ART) immediately in patients who present for care with nontuberculosis AIDS-related opportunistic infections (OIs; JW AIDS Clin Care Jun 22 2009), but little is known about the cost-effectiveness of this strategy in the U.S.

To explore this issue, investigators used a mathematical simulation model, incorporating data from the 262 adults who participated in ACTG A5164 in the U.S. (88% men). Immediate ART initiation (within 2 weeks after OI diagnosis) was compared with deferred ART initiation (at least 4 weeks after OI diagnosis). Key assumptions of the model included a 7% absolute risk for immune reconstitution inflammatory syndrome, an 87% rate of linkage to…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Immediate ART Following Diagnosis of an AIDS-Related OI: Is It Cost-Effective?

Topics

Reviewing Author